Julie Hallet: New study on NETs liver metastases from unknown primary by Patrick Starlinger and team Mayo Clinic

Julie Hallet, Pancreatic and Gastrointestinal Surgical Oncologist at IHPBA, shared a post on LinkedIn:

“New study on Neuroendocrine Tumors (NETs) liver metastases from unknown primary, a rare entity and can have good results with cytoreduction.

32 patients cytoreduction results are comparable to Small Bowel (SB) -NETs, including 10-year Overall Survival (OS) 53% and hepatic Progression-Free Survival (PFS) 26 months median.

Good to know to consider surgery for those patients. Also have to wonder if unknown primary are reallt undetected SB NETs?

Paper in Annals of Surgical Oncology by Patrick Starlinger and team Mayo Clinic.”

Additional information
Source: Julie Hallet/LinkedIn